RENEURON GRP PLC LS-01
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in… Read more
Market Cap & Net Worth: RENEURON GRP PLC LS-01 (RQE1)
RENEURON GRP PLC LS-01 (F:RQE1) has a market capitalization of $2.00 Million (€1.94 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #34858 globally and #4053 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying RENEURON GRP PLC LS-01's stock price €0.03 by its total outstanding shares 57173800 (57.17 Million).
RENEURON GRP PLC LS-01 Market Cap History: 2015 to 2024
RENEURON GRP PLC LS-01's market capitalization history from 2015 to 2024. Data shows change from $183.16 Million to $2.00 Million (-41.32% CAGR).
RENEURON GRP PLC LS-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how RENEURON GRP PLC LS-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RQE1 by Market Capitalization
Companies near RENEURON GRP PLC LS-01 in the global market cap rankings as of March 19, 2026.
Key companies related to RENEURON GRP PLC LS-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
RENEURON GRP PLC LS-01 Historical Marketcap From 2015 to 2024
Between 2015 and today, RENEURON GRP PLC LS-01's market cap moved from $183.16 Million to $ 2.00 Million, with a yearly change of -41.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | €2.00 Million | -1.45% |
| 2023 | €2.02 Million | -59.88% |
| 2022 | €5.05 Million | -90.17% |
| 2021 | €51.35 Million | -1.69% |
| 2020 | €52.23 Million | -41.51% |
| 2019 | €89.29 Million | +195.38% |
| 2018 | €30.23 Million | +76.04% |
| 2017 | €17.17 Million | -85.00% |
| 2016 | €114.48 Million | -37.50% |
| 2015 | €183.16 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 27th, 2025 the market cap of RENEURON GRP PLC LS-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.00 Million USD |
| MoneyControl | $2.00 Million USD |
| MarketWatch | $2.00 Million USD |
| marketcap.company | $2.00 Million USD |
| Reuters | $2.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.